On June 15, the official website of the National Medical Products Administration (NMPA) showed that Zelgen Pharmaceutical’s JAK inhibitor jaktinib (formerly known as Jackitinib) has been approved for marketing for severe alopecia areata.
Jaktinib is a novel JAK inhibitor that significantly inhibits all four JAK kinase subtypes: JAK1, JAK2, JAK3, and TYK2. It can effectively suppress inflammation and T-cell overactivation, while also significantly increasing dermal thickness, promoting hair follicle regeneration, and increasing hair follicle density. In May 2025, jaktinib was first approved for marketing in China for the treatment of adult patients with intermediate- or high-risk primary myelofibrosis (PMF), post-polycythemia vera myelofibrosis (PPV-MF), and post-essential thrombocythemia myelofibrosis (PET-MF), to treat disease-related splenomegaly or disease-related symptoms.
This approval for alopecia areata is based on positive results from the Phase III ZGJAK018 study. Results showed that after 24 weeks of treatment, the proportion of patients in the jaktinib group achieving a Severity of Alopecia Tool (SALT) score ≤20 was significantly higher than in the placebo group. Currently, 5 JAK inhibitors have been approved globally for the treatment of alopecia areata.
The other 4 are baricitinib (Eli Lilly), ritlecitinib (Pfizer), deuruxolitinib (Sun Pharma), and ivarmacitinib (Hengrui Medicine).